Metagenomic next-generation sequencing-guided antimicrobial treatment versus conventional antimicrobial treatment in early severe community-acquired pneumonia among immunocompromised patients (MATESHIP): A study protocol

Shaohua Fan, Min Si, Nana Xu, Meichen Yan, Mingmin Pang, Guangfeng Liu, Jibin Gong, Hao Wang, Shaohua Fan, Min Si, Nana Xu, Meichen Yan, Mingmin Pang, Guangfeng Liu, Jibin Gong, Hao Wang

Abstract

Background: Severe community-acquired pneumonia (SCAP) is the main cause of mortality in immunocompromised patients. Compared with conventional microbiological tests (CMT), metagenomic next-generation sequencing (mNGS) can quickly and simultaneously detect a wide array of bacteria, viruses, and fungi in an unbiased manner. It is increasingly used for severe respiratory infectious diseases, especially for immunocompromised patients. However, the effects of mNGS-based antimicrobial treatment procedures on clinical outcomes in immunocompromised patients with SCAP have not been evaluated.

Methods/design: The MATESHIP study is a prospective, multicenter, parallel-group, open-label, randomized controlled trial from 20 ICUs in university hospitals and academic teaching hospitals across Shandong Province, China. We will enroll 342 immunocompromised patients with early onset SCAP who are admitted to an intensive care unit (ICU). Participants will be randomly allocated to an mNGS-guided treatment group or a conventional treatment group (guided by CMT), according to centrally computer-based block randomization stratified by participating centers. Participants will undergo CMT tests using appropriate lower respiratory tract (LRT) and other necessary specimens, with or without mNGS tests using LRT specimens. The primary outcomes will be: (1) The relative change in Sequential Organ Failure Assessment (SOFA) score from randomization to day 5, day 7, day 10, or the day of ICU discharge/death; and (2) the consumption of antimicrobial agents during ICU stay (expressed as defined daily doses). The secondary outcome measures will be: days from randomization to initiation of definitive antimicrobial treatment; overall antimicrobial agent use and cost; total cost of hospitalization; length of ICU stay; 28- and 90-day mortality; and clinical cure rate. This study hypothesizes that mNGS-guided treatment will decrease the degree of organ dysfunction/failure, the consumption of antimicrobial agents, and mortality, while the cure rate will be increased, and the time to initiation of appropriate therapy will be advanced.

Discussion: The MATESHIP study will evaluate for the first time whether mNGS-guided antimicrobial therapy improves the outcomes of SCAP in an immunocompromised population, and provide high-level evidence on the application of mNGS in the management of this population.

Clinical trial registration: [ClinicalTrials.gov], identifier [NCT05290454].

Keywords: antimicrobial therapy; community-acquired pneumonia; immunocompromised patient; immunosuppression; metagenomic next generation sequencing.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Fan, Si, Xu, Yan, Pang, Liu, Gong and Wang.

References

    1. Aliberti S., Dela C. C. S., Amati F., Sotgiu G., Restrepo M. I. (2021). Community-acquired pneumonia. Lancet 398 906–919. 10.1016/S0140-6736(21)00630-9
    1. Azar M. M., Schlaberg R., Malinis M. F., Bermejo S., Schwarz T., Xie H. (2021). Added diagnostic utility of clinical metagenomics for the diagnosis of pneumonia in immunocompromised adults. Chest 159 1356–1371. 10.1016/j.chest.2020.11.008
    1. Azoulay E., Lemiale V., Mokart D., Nseir S., Argaud L., Pene F., et al. (2018). Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: the HIGH randomized clinical trial. JAMA 320 2099–2107. 10.1001/jama.2018.14282
    1. Azoulay E., Mokart D., Kouatchet A., Demoule A., Lemiale V. (2019). Acute respiratory failure in immunocompromised adults. Lancet Respir. Med. 7 173–186. 10.1016/S2213-2600(18)30345-X
    1. Azoulay E., Russell L., Van de Louw A., Metaxa V., Bauer P., Povoa P. (2020). Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med. 46 298–314. 10.1007/s00134-019-05906-5
    1. Cao B., Huang Y., She D. Y., Cheng Q. J., Fan H., Tian X. L., et al. (2018). Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese thoracic society, Chinese medical association. Clin. Respir. J. 12 1320–1360. 10.1111/crj.12674
    1. Casto A. M., Fredricks D. N., Hill J. A. (2021). Diagnosis of infectious diseases in immunocompromised hosts using metagenomic next generation sequencing-based diagnostics. Blood Rev. 53:100906. 10.1016/j.blre.2021.100906
    1. Cheng P., Chen H. H., Jiang Y. H., Hsiao T. H., Wang C. Y., Wu C. (2021). Using RNA-Seq to investigate immune-metabolism features in immunocompromised patients with sepsis. Front. Med. 8:747263. 10.3389/fmed.2021.747263
    1. Chiu C. Y., Miller S. A. (2019). Clinical metagenomics. Nat. Rev. Genet. 20 341–355. 10.1038/s41576-019-0113-7
    1. Di Pasquale M. F., Sotgiu G., Gramegna A., Radovanovic D., Terraneo S., Reyes L. F., et al. (2019). Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin. Infect. Dis. 68 1482–1493. 10.1093/cid/ciy723
    1. Diao Z., Han D. S., Zhang R., Li J. M. (2022). Metagenomics next-generation sequencing tests take the stage in the diagnosis of lower respiratory tract infections. J. Adv. Res. 38 201–212. 10.1016/j.jare.2021.09.012
    1. Evans L., Rhodes A., Alhazzani W., Antonelli M., Coopersmith C. M., French C., et al. (2021). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 47 1181–1247. 10.1007/s00134-021-06506-y
    1. Fung M., Babik J. M. (2021). COVID-19 in immunocompromised hosts: what we know so far. Clin. Infect. Dis. 72 340–350. 10.1093/cid/ciaa863
    1. Garnacho-Montero J., Barrero-García I., Gomez-Prieto M. G., Martin-Loeches I. (2018). Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev. Anti Infect. Ther. 16 667–677. 10.1080/14787210.2018.1512403
    1. Gu W., Miller S., Chiu C. Y. (2019). Clinical metagenomic next-generation sequencing for pathogen detection. Annu. Rev. Pathol. 14 319–338. 10.1146/annurev-pathmechdis-012418-012751
    1. Hogan C. A., Yang S. X., Garner O. B., Green D. A., Gomez C. A., Dien Bard J., et al. (2021). Clinical impact of metagenomic next-generation sequencing of plasma cell-free DNA for the diagnosis of infectious diseases: a multicenter retrospective cohort study. Clin. Infect. Dis. 72 239–245. 10.1093/cid/ciaa035
    1. Jain S., Self W. H., Wunderink R. G., Fakhran S., Balk R., Bramley A. M., et al. (2015). Community-acquired pneumonia requiring hospitalization among U.S. Adults. N. Engl. J. Med. 373 415–427. 10.1056/NEJMoa1500245
    1. Langelier C., Zinter M. S., Kalantar K., Yanik G. A., Christenson S., Donovan O. B., et al. (2018). Metagenomic sequencing detects respiratory pathogens in hematopoietic cellular transplant patients. Am. J. Respir. Crit. Care Med. 197 524–528. 10.1164/rccm.201706-1097LE
    1. Laterre P. F., Colin G., Dequin P. F., Dugernier T., Boulain T., Azeredo D. S. S., et al. (2019). CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 19 620–630. 10.1016/S1473-3099(18)30805-3
    1. Li H., Durbin R. (2009). Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics 25 1754–1760. 10.1093/bioinformatics/btp324
    1. Li H., Gao H., Meng H., Wang Q., Li S., Chen H., et al. (2018). Detection of pulmonary infectious pathogens from lung biopsy tissues by metagenomic next-generation sequencing. Front. Cell Infect. Microbiol. 8:205. 10.3389/fcimb.2018.00205
    1. Li Y., Sun B., Tang X., Liu Y. L., He H. Y., Li X. Y., et al. (2020). Application of metagenomic next-generation sequencing for bronchoalveolar lavage diagnostics in critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 39 369–374. 10.1007/s10096-019-03734-5
    1. Metlay J. P., Waterer G. W., Long A. C., Anzueto A., Brozek J., Crothers K. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of america. Am. J. Respir. Crit. Care Med. 200 e45–e67. 10.1164/rccm.201908-1581ST
    1. Miao Q., Ma Y., Wang Q., Pan J., Zhang Y., Jin W., et al. (2018). Microbiological diagnostic performance of metagenomic next-generation sequencing when applied to clinical practice. Clin. Infect. Dis. 67 S231–S240. 10.1093/cid/ciy693
    1. Miller S., Naccache S. N., Samayoa E., Messacar K., Arevalo S., Federman S., et al. (2019). Laboratory validation of a clinical metagenomic sequencing assay for pathogen detection in cerebrospinal fluid. Genome Res. 29 831–842. 10.1101/gr.238170.118
    1. Nair G. B., Niederman M. S. (2020). Updates on community acquired pneumonia management in the ICU. Pharmacol. Ther. 217:107663. 10.1016/j.pharmthera.2020.107663
    1. Pan T., Tan R., Qu H., Weng X., Liu Z., Li M. (2018). Next-generation sequencing of the BALF in the diagnosis of community-acquired pneumonia in immunocompromised patients. J. Infect. 79 61–74. 10.1016/j.jinf.2018.11.005
    1. Parize P., Bamba G., Dubois M., Join-Lambert O., Leruez-Ville M., Nassif X., et al. (2017). Untargeted next-generation sequencing-based first-line diagnosis of infection in immunocompromised adults: a multicentre, blinded, prospective study. Clin. Microbiol. Infect. 23 574.e1–574.e6. 10.1016/j.cmi.2017.02.006
    1. Peng J. M., Du B., Qin H. Y., Wang Q., Shi Y. (2021). Metagenomic next-generation sequencing for the diagnosis of suspected pneumonia in immunocompromised patients. J. Infect. 82 22–27. 10.1016/j.jinf.2021.01.029
    1. Ramirez J. A., Musher D. M., Evans S. E., Dela Cruz C., Crothers K. A., Hage C. A. (2020). Management of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest 158 1896–1911. 10.1016/j.chest.2020.05.598
    1. Schlaberg R., Chiu C. Y., Miller S., Procop G. W., Weinstock G. (2017). Validation of metagenomic next-generation sequencing tests for universal pathogen detection. Arch. Pathol. Lab Med. 141 776–786. 10.5858/arpa.2016-0539-RA
    1. Sousa D., Justo I., Domínguez A., Manzur A., Izquierdo C., Ruiz L., et al. (2013). Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin. Microbiol. Infect. 19 187–192. 10.1111/j.1469-0691.2012.03765.x
    1. Sun T., Wu X. J., Cai Y., Zhai T. S., Huang L. N., Zhang Y. (2021). Metagenomic next-generation sequencing for pathogenic diagnosis and antibiotic management of severe community-acquired pneumonia in immunocompromised adults. Front. Cell. Infect. Microbiol. 11:661589. 10.3389/fcimb.2021.661589
    1. Torres A., Chalmers J. D., Dela C. C. S., Dominedo C., Kollef M., Martin-Loeches I., et al. (2019). Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med. 45 159–171. 10.1007/s00134-019-05519-y
    1. Yin M., Zheng Y., Zhang L., Qin W., Han H., Wu D., et al. (2022). The real-life performance of metagenomic next-generation sequencing in sepsis. J. Infect. 84 418–467. 10.1016/j.jinf.2021.11.018
    1. Zanella M. C., Cordey S., Laubscher F., Docquier M., Van Delden C., et al. (2021). Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease. Microbiome 9:28. 10.1186/s40168-020-00953-3
    1. Zhan Y. Q., Xu T., He F. S., Li Z. T., Li S. Q., Xie M. (2021). Clinical evaluation of a metagenomics-based assay for pneumonia management. Front. Microbiol. 12:751073. 10.3389/fmicb.2021.751073
    1. Zhao Z., Song J., Yang C., Yang L., Chen J., Li X. (2021). Prevalence of fungal and bacterial co-infection in pulmonary fungal infections: a metagenomic next generation sequencing-based study. Front. Cell. Infect. Microbiol. 11:749905. 10.3389/fcimb.2021.749905
    1. Zinter M. S., Dvorak C. C., Mayday M. Y., Iwanaga K., Ly N. P., McGarry M. E., et al. (2019). Pulmonary metagenomic sequencing suggests missed infections in immunocompromised children. Clin. Infect. Dis. 68 1847–1855. 10.1093/cid/ciy802

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe